Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.”In the company’s words, NCT05938036 on ClinicalTrials.gov
- Main trialPhase 2
- “A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.”In the company’s words, NCT05938036 on ClinicalTrials.gov
Other drugs for Acute Respiratory Distress Syndrome (ARDS)
- APC-0101Aerogen Pharma Limited · Phase 3
- TozorakimabAstraZeneca · Phase 3
- ExoFloDirect Biologics, LLC · Phase 3
- Aerosolized CalfactantONY · Phase 3
- LEAF-4L6715LEAF4Life, Inc. · Phase 3
- STSA-1002Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3
Coming up1
- 1 May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 1 May 2027 | Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS | |
| Phase 1Completed | 18 May 2023 | First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026